Multicenter randomized, placebo-controlled, double-blind clinical trial assessing the effects of steroid administration on fatigue and QOL in advanced cancer patients
- Conditions
- Cancer
- Registration Number
- JPRN-UMIN000011913
- Lead Sponsor
- Kyoto University, School of Public Health
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 80
Not provided
(1) The patient was administered a steroid orally or by injection 1 week or less before enrollment. (2) The patient was administered a synthetic progestin 4 weeks or less before enrollment. (3) The patient had surgery 4 weeks or less before the time of enrollment. (4) The patient was undergoing radiation therapy at the time of enrollment. (5) The patient had chemotherapy 4 weeks or less before enrollment. Alternatively, it has been 4 weeks or less after the patient completed chemotherapy. (6) The patient has a prior history of diabetes that involves drug treatment. (7) The patient clearly has an infectious disease complication. (8) The patient has a peptic ulcer as a complication that involves drug treatment. (9) The patient has a mental disorder (including delirium) related to cognitive function. (10) The patient has contraindications to betamethasone tablets that are listed in the package insert. (11) For any other reason, the patient is judged by the physician in charge to be inappropriate as a subject in the present study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method